**3. Case study**

#### **3.1 Aim and scope**

In this study we will show the results obtained at our center with one of the most recent devices for the transvaginal correction of female POP, the Restorelle® singleincision mesh (Coloplast, USA). This product was later withdrawn from the market along with other transvaginal prosthetic devices for the correction of POP (April 2019), following its ban by the FDA.

Restorelle® Direct Fix Mesh products incorporate Smartmesh® technology (physiologically compatible ultralight mesh). It provides long-term strength while maintaining the vaginal elasticity of natural tissue. Its placement allows for an anterior sacrospinous ligament approach, using a disposable device (Digitex®) designed to place sutures without direct visualization. The proximal arms of the mesh are sutured to the anterior sacrospinous ligament and the distal arms of the mesh are sutured to the arch of the pelvic tendinous fascia.

#### **3.2 Study design and material and methods**

Retrospective study of patients who underwent surgical correction of POP in the same center between January 2016 and December 2017 with the Restorelle®

*Surgical Treatment of Pelvic Organ Prolapse DOI: http://dx.doi.org/10.5772/intechopen.100232*

device. We analyzed demographic variables, prolapse characteristics, associated symptoms, gynecological history, recurrence, and degree of satisfaction taken from the existing medical history. The degree of POP was evaluated according to the Baden-Walker classification. The surgical indication was symptomatic patients with grade ≥ 2 POP (primary or recurrent). All interventions were performed by a single surgeon after an antibiotic prophylaxis protocol.
